A Phase 4 interventional study of amlodipine/valsartan in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Turkey. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.
Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 28th largest by enrollment, is one of 7 that started in 2014, is one of 7 in phase 4, and was the 15th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18–75
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is below the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 314 across the 34 interventional studies. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Essential Hypertension by Novartis: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 4, and was the 25th registered.
Novartis’s Essential Hypertension studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing amlodipine in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
Drug: amlodipine/valsartan
Drug pages: Amlodipine · Valsartan
Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Control rate of BP defined as BP lower than 140/90 mmHg at office visits
Time frame: At week 4 and 8
Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8
Change in systolic blood pressure measured in office from baseline at week 4 and 8.
Time frame: baseline, week 4, week 8
Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8
Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.
Time frame: baseline, week 4, week 8
Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\>100 mEq/day)
Time frame: At week 4 and 8
SBP and DBP in Patients With High Sodium Intake at Week 4 and 8
Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.
Time frame: At week 4 and 8
One hundred thirty patients were screened and 115 were enrolled into the trial.
| Milestone | Amlodipine/Valsartan |
|---|---|
| Started | 115 |
| Completed | 100 |
| Not completed | 15 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Lost to follow-up | 5 |
Control rate of BP defined as BP lower than 140/90 mmHg at office visits
| Percentage of Participants | Amlodipine/Valsartan |
|---|---|
| Week 4 Systolic (n=100) | 47.0 |
| Week 4 Diastolic (n=100) | 78.0 |
| Week 4 Overall Blood Pressure(n=100) | 45.0 |
| Week 8 Systolic(n=91) | 70.3 |
| Week 8 Diastolic (n=91) | 82.4 |
| Week 8 Overall Blood Pressure (n=91) | 67.0 |
| Week 8 Systolic (LOCF) (n=100) | 68.0 |
| Week 8 Diastolic (LOCF) (n=100) | 81.0 |
| Week 8 Overall Blood Pressure (LOCF) (n=100) | 65.0 |
Change in systolic blood pressure measured in office from baseline at week 4 and 8.
| mmHg | Amlodipine/Valsartan |
|---|---|
| Systolic blood pressure (SBP) Day 0 (n=100) | 164.3 ± 13.2 |
| Systolic blood pressure (SBP) Week 4 (n=100) | 140.17 ± 14.05 |
| Systolic blood pressure (SBP) Week 8 (n=91) | 134.04 ± 13.51 |
| Systolic blood pressure (SBP) Week 8 LOCF (n=100) | 134.71 ± 13.37 |
| Decrease in Systolic Week 4 (n=100) | 24.15 ± 18.18 |
| Decrease in Systolic Week 8 (n=91) | 30.22 ± 18.25 |
| Decrease in Systolic BP Week 8 LOCF (n=100) | 29.61 ± 17.81 |
Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.
| mmHg | Amlodipine/Valsartan |
|---|---|
| Diastolic blood pressure (DBP) Day 0 (n=100) | 96.66 ± 12.68 |
| Diastolic blood pressure (DBP) Week 4 (n=100) | 82.0 ± 9.88 |
| Diastolic blood pressure (DBP) Week 8 (n=91) | 81.04 ± 8.66 |
| Diastolic blood pressure (DBP) Week 8 LOCF (n=100) | 81.37 ± 8.69 |
| Decrease in Diastolic BP Week 4 (n=100) | 14.66 ± 12.58 |
| Decrease in Diastolic BP Week 8 (n=91) | 15.54 ± 13.19 |
| Decrease in Diastolic BP Week 8 LOCF (n=100) | 15.29 ± 12.73 |
Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\>100 mEq/day)
| Percentage of participants | Amlodipine/Valsartan |
|---|---|
| Week 4 (n=70) | 68.6 |
| Week 8 (n=64) | 64.1 |
| Week 8 LOCF (n=70) | 62.9 |
Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.
| mmHg | Amlodipine/Valsartan |
|---|---|
| SBP at Week 4 (n=70) | 140.01 ± 13.67 |
| SBP at Week 8 (n=64) | 134.20 ± 13.24 |
| SBP at Week 8 LOCF (n=70) | 134.84 ± 13.17 |
| DBP at Week 4 (n=70) | 81.73 ± 10.26 |
| DBP at Week 8 (n=64) | 81.23 ± 8.80 |
| DBP at Week 8 LOCF (n=70) | 81.47 ± 8.91 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine/Valsartan | — | 3/110 (2.7%) | 76/110 (69.1%) |
| Event | Amlodipine/Valsartan |
|---|---|
| DeathGeneral disorders | 1/110 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/110 |
| NephrolithiasisRenal and urinary disorders | 1/110 |
| Event | Amlodipine/Valsartan |
|---|---|
| Left ventricular dysfunctionCardiac disorders | 34/110 |
| Left ventricular hypertrophyCardiac disorders | 30/110 |
| Mitral valve incompetenceCardiac disorders | 16/110 |
| Aortic valve incompetenceCardiac disorders | 10/110 |
| Tricuspid valve incompetenceCardiac disorders | 8/110 |
| Urine sodium increasedInvestigations | 8/110 |
| AnaemiaBlood and lymphatic system disorders | 7/110 |
| MicroalbuminuriaRenal and urinary disorders | 6/110 |
| Diastolic dysfunctionCardiac disorders | 5/110 |
| Left atrial dilatationCardiac disorders | 4/110 |
The baseline population was the ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0)
| Age, Continuous(years) | Amlodipine/Valsartan |
|---|---|
| Mean | 55.06 ± 11.22 |
| Sex: Female, Male(Participants) | Amlodipine/Valsartan |
|---|---|
| Female | 55 |
| Male | 45 |
| Systolic blood pressure(mmHG) | Amlodipine/Valsartan |
|---|---|
| Mean | 164.3 ± 13.2 |
| Diastolic blood pressure(mmHg) | Amlodipine/Valsartan |
|---|---|
| Mean | 96.7 ± 12.7 |
| Heart rate(beats/min) | Amlodipine/Valsartan |
|---|---|
| Mean | 80.15 ± 10.00 |
| Body mass index(kg/m^2) | Amlodipine/Valsartan |
|---|---|
| Mean | 31.19 ± 5.32 |
The record gives a start of Feb 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Valsartan